MedTrace Logo

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

NCT04832399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Natalizumab

As described in the treatment arm.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-12
Primary Completion
2023-10-02
Completion
2023-10-02
FDA Drug
Yes

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04832399 on ClinicalTrials.gov